Metaspacex Limited 中國數智科技集團有限公司 (Incorporated in the Cayman Islands with limited liability) ( 於開曼群島註冊成立的有限公司 ) (Stock Code 股份代號: 1796) N OT IF IC ATI ON LET TE R 通 知 信 函 Dear Non-registered Shareholders(1) , 17 December 2025 Metaspacex Limited (the "Company") – Notice of Publication of 2025 Interim Report (the "Current Corporate Communication(s)") The English and Chinese versions of the Company's Current Corporate Communication (s) are available on the Company's website at www.01796.com.cn (the "Company's w ...

It is the responsibility of you to provide a functional email address. If you have not provided your email address to the Com pany or need to update your email address, the Company recommends you provide your email address by completing, signing the enclosed Request Form and returning it to the Hong Kong Branch Share Registrar at the above-mentioned address by post or by email to 1796-ecom@boardroomlimited.com. If the Company does not have your functional email address, until such time that the functional e ...

Financial Performance - For the six months ended September 30, 2025, the group's revenue decreased by approximately HKD 28.4 million or 20.5% to about HKD 110.1 million, compared to HKD 138.5 million for the same period in 2024[10] - The gross profit slightly decreased by approximately HKD 0.1 million or 3.0% to about HKD 5.1 million, with a gross profit margin of 4.6%, up from 3.8% in the previous period, attributed to strict cost control measures[11] - The net loss for the six months ended September 30, 2025, was approximately HKD 3.7 million, a decrease of about HKD 6.8 million compared to a net loss of HKD 10.5 million in the same period of 2024[15] - The loss before tax for the six months ended September 30, 2025, was HKD 3.75 million, compared to a loss of HKD 10.47 million for the same period in 2024, indicating an improvement in performance[29] - For the six months ended September 30, 2025, the company reported a loss attributable to equity holders of HKD 3,746,000, compared to a loss of HKD 10,465,000 for the same period in 2024, representing a 64.1% improvement in losses year-over-year[52] Cost Management - Administrative and other operating expenses decreased by HKD 3.5 million or 27.0% to approximately HKD 9.4 million, compared to HKD 12.9 million in the same period last year[13] - Financial costs reduced by approximately HKD 0.7 million or 23.4% to about HKD 2.1 million, mainly due to a decrease in the average interest rate on borrowings[14] - The increase in gross profit margin is a result of the implementation of strict cost control measures in response to a challenging business environment[11] - Total employee costs for the six months ended September 30, 2025, were approximately HKD 8.9 million, down from HKD 12.2 million for the same period in 2024[25] - The company reported a significant decrease in subcontracting costs, which fell to HKD 62,127,000 in 2025 from HKD 96,166,000 in 2024, a reduction of 35.4%[48] Cash Flow and Liquidity - The total cash and cash equivalents amount to approximately HKD 44.3 million, an increase from HKD 43.1 million as of March 31, 2025, due to a net cash inflow of approximately HKD 1.2 million from operating and financing activities[16] - The net cash used in operating activities for the six months ended September 30, 2025, was HKD (1,332,000), an improvement compared to HKD (10,362,000) in the previous year[33] - The company’s financing activities generated a net cash inflow of HKD 2,513,000 for the six months ended September 30, 2025, compared to a net cash outflow of HKD (500,000) in the previous year[33] - Cash and cash equivalents increased to HKD 44,270,000 as of September 30, 2025, from HKD 38,665,000 at the end of the previous year[33] Economic Outlook - The group anticipates stable and moderate growth in the Hong Kong economy for the second half of 2025, with an expected GDP growth rate between 2% and 3% for the year[9] - The overall business environment remains uncertain due to geopolitical tensions, competitive pressures, and changing trade policies[8] Business Strategy and Opportunities - The group is actively exploring new business opportunities, particularly in the Web3.0 and new energy sectors, which are strongly supported by government policies[9] - The company has decades of experience in the renovation contracting industry, providing services for both new and existing buildings[8] Shareholder Information - As of September 30, 2025, the company's issued share capital is HKD 4.8 million, with 480,000,000 shares outstanding at HKD 0.01 per share[16] - The company did not declare or recommend any interim dividend for the six months ended September 30, 2025, consistent with the previous year[50] - The company has adopted a share option scheme allowing for a maximum of 48,000,000 shares to be granted, which constitutes 10% of the issued shares as of the report date[77] - No share options have been granted, exercised, canceled, or lapsed since the adoption of the share option scheme on December 6, 2018, and there are no unexercised options as of September 30, 2025[77] Corporate Governance - The company has adopted and complied with the Corporate Governance Code, with no applicable code provisions breached during the reporting period[90] - The audit committee, established on December 28, 2018, reviewed and approved the unaudited condensed consolidated interim financial statements for the six months ending September 30, 2025[93] - The company has maintained sufficient public float as required by listing rules as of September 30, 2025[88] Assets and Liabilities - The company's total non-current liabilities increased to HKD 67,903,000 as of September 30, 2025, compared to HKD 63,313,000 as of March 31, 2025[31] - The total equity of the company decreased to HKD 72,814,000 as of September 30, 2025, down from HKD 76,560,000 as of March 31, 2025[31] - Trade receivables as of September 30, 2025, amounted to HKD 15,328,000, a decrease from HKD 18,182,000 as of March 31, 2025, indicating a reduction of 15.3%[55] - Contract assets increased to HKD 117,066,000 as of September 30, 2025, compared to HKD 109,693,000 as of March 31, 2025, an increase of 6.6%[58] - Total borrowings amounted to HKD 53,897,000 as of September 30, 2025, up from HKD 50,897,000 as of March 31, 2025[66] Management and Personnel - The company recorded a total of HKD 287,000 in compensation for key management personnel for the six months ended September 30, 2025, a decrease from HKD 1,134,000 for the same period in 2024[72] - The company has a future lease liability of HKD 1,178,000 as of September 30, 2025, down from HKD 1,632,000 as of March 31, 2025[64]

Market Overview - The Hong Kong stock market opened high but experienced fluctuations, with the Hang Seng Index up 0.09% at 25,563.05 points, while the Tech Index fell 0.65% to 5,544.57 points [1] - Major tech stocks showed mixed performance, with Alibaba down 0.78%, Tencent down 0.08%, and JD.com down 0.44%, while Xiaomi rose 0.81% and Meituan increased by 0.8% [1] - Lithium battery stocks performed well, with CATL rising over 2%, while chip stocks weakened, with ZTE down over 9% [1] Company News - Sunny Optical Technology (02382.HK) reported November mobile lens shipments of approximately 119 million units, a month-on-month decrease of 2.3% but a year-on-year increase of 7.5% [2] - Q Technology (01478.HK) saw November mobile camera module sales of 38.05 million units, down 13.6% month-on-month and down 5.6% year-on-year [2] - Yuanyuan Group (00551.HK) reported a net operating income of approximately $660 million in November, a year-on-year decrease of 3.1% [2] - Baoshan International (03813.HK) reported a net operating income of 1.172 billion yuan in November, down 5.1% year-on-year [3] - Morning News Technology (02000.HK) reported unaudited revenue of 44.3 million HKD in November, up 48.4% month-on-month and 19.73% year-on-year [4] - Ocean Group (03377.HK) reported a cumulative contract sales amount of approximately 23.79 billion yuan for the first 11 months [5] - Jianye Real Estate (00832.HK) reported a total property contract sales amount of 7.168 billion yuan for the first 11 months, a year-on-year decrease of 16.3% [6] - Yuzhou Group (01628.HK) reported a cumulative sales amount of 6.196 billion yuan for the first 11 months [7] - COFCO Joycome (01610.HK) reported a pig slaughtering volume of 559,000 heads in November, a month-on-month decrease of 4.44% [8] - CSPC Pharmaceutical Group (01093.HK) received clinical trial approval in the U.S. for its fully human anti-ACTRIIA/IIB monoclonal antibody (JMT206) [9] - China Digital Technology (01796.HK) entered into a strategic cooperation agreement with Xinhua Pharmaceutical [10] - China Hongqiao (01378.HK) announced that the acquisition of Hongtu Industrial by Hongchuang Holdings was approved by the Shenzhen Stock Exchange's M&A Review Committee [11] - CICC (03908.HK) plans to issue perpetual subordinated bonds of no more than 3 billion yuan [12] Institutional Insights - Everbright Securities noted that compared to previous bull markets, the current index has significant upside potential, but the duration of the bull market may be more important than the magnitude of the increase [13] - Guosen Securities indicated that the recent adjustments in the Hong Kong market could open up space for a market rise in 2026, with over 110 billion yuan of net inflow from southbound funds in November [13] - CITIC Securities predicted a second round of valuation recovery for the Hong Kong market in 2026, emphasizing the need to focus on "earnings certainty + valuation elasticity" in sectors like technology, pharmaceuticals, resources, and essential consumption [13]

Core Viewpoint - The strategic cooperation agreement between China Digital Technology (01796) and Xinhua Pharmaceutical Development (Qianjiang) aims to explore collaboration opportunities in traditional Chinese medicine and the health industry in China [1] Group 1: Strategic Cooperation - The agreement focuses on resource development, production, supply chain, modern product research and development, marketing, and capital market collaboration in the traditional Chinese medicine sector [1] - The goal of the strategic cooperation is to achieve resource complementarity and synergistic development between the two companies [1] Group 2: Technological Integration - Both parties intend to leverage big data and advanced intelligent computing to drive the standardization, modernization, and marketing of traditional Chinese medicine through artificial intelligence [1] Group 3: Management and Progress - The companies will hold senior management meetings periodically to discuss the forms, directions, and other related matters of the cooperation projects based on market conditions and collaboration progress [1]

Core Viewpoint - The strategic cooperation agreement between China Digital Technology (01796) and Xinhua Pharmaceutical Development (Qianjiang) aims to explore collaboration opportunities in traditional Chinese medicine and the health industry in China [1] Group 1: Strategic Cooperation - The agreement focuses on resource development, production, supply chain, modern product research and development, marketing, and capital market collaboration in the traditional Chinese medicine sector [1] - The goal of the strategic cooperation is to achieve resource complementarity and synergistic development [1] Group 2: Technological Integration - Both parties intend to leverage big data and advanced intelligent computing to drive the standardization, modernization, and marketing of traditional Chinese medicine through artificial intelligence [1] Group 3: Management Engagement - The companies will hold senior management meetings periodically to discuss the forms, directions, and other related matters of the cooperation projects based on market conditions and progress [1]

Core Viewpoint - China Digital Technology (01796.HK) has entered into a strategic cooperation agreement with Xinhua Pharmaceutical Development (Qianjiang) Co., Ltd. to explore opportunities in traditional Chinese medicine and the health industry by leveraging market growth potential and policy opportunities [1] Group 1: Strategic Cooperation Agreement - The agreement aims to establish collaboration in areas such as Chinese medicine resource development, production and supply chain, modern Chinese medicine product research and development, production and marketing, as well as capital market and industry cooperation [1] - The goal of the strategic cooperation is to achieve resource complementarity and synergistic development between the two companies [1] Group 2: Focus on Technology and Innovation - Both parties will engage in deep cooperation, utilizing big data and advanced intelligent computing to drive the standardization, modernization, and marketing of Chinese medicine through artificial intelligence [1] - Senior management meetings will be held periodically to discuss the forms, directions, and other related matters of cooperation projects based on market conditions and progress [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 Metaspacex Limited 中國數智科技集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號︰1796） 自願性公告 戰略合作協議 中 國 數 智 科 技 集 團 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）謹 此 發 表 自 願 性 公 告，向 本 公 司 股 東 及 有 意 投 資 者 提 供 有 關 本 集 團 最 新 業 務 發 展 的 最 新 情 況。 訂立戰略合作協議 本 公 司 董 事（「董 事」）會（「董事會」）謹 此 宣 佈，於 二 零 二 五 年 十 二 月 十 日，本 公 司 與 新 華 醫 藥 發 展（潛 江）有 限 公 司（「新華醫藥」）訂 立 了 一 項 戰 略 合 作 協 議（「戰 略 合作協議」）。 根 據 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國數智科技集團有限公司 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01796 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 1,000,000,000 | | HKD | | 0.01 | HKD | | 10,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | 本月 ...

Core Viewpoint - China Digital Technology (01796) reported a revenue of approximately HKD 110 million for the six months ending September 30, 2025, representing a year-on-year decrease of 20.49% [1] - The company recorded a loss attributable to equity holders of approximately HKD 3.746 million, which is a 64.2% reduction compared to the previous year [1] - The decrease in revenue is primarily due to the completion of large projects and a reduction in the number of large projects available in the market [1] Financial Performance - Revenue for the period was approximately HKD 110 million, down 20.49% year-on-year [1] - Loss attributable to equity holders was approximately HKD 3.746 million, a decrease of 64.2% year-on-year [1] - Basic loss per share was HKD 0.78 [1] Project and Market Analysis - The decline in revenue is attributed to the completion of large projects undertaken by the company [1] - There has been a noticeable decrease in the number of large projects available for the company to undertake in the market [1]